AIM ImmunoTech Inc (AMEX: AIM) on Friday, plunged -8.18% from the previous trading day, before settling in for the closing price of $0.29. Within the past 52 weeks, AIM’s price has moved between $0.25 and $0.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -2.98% over the past five years. The company achieved an average annual earnings per share of 45.83%. With a float of $51.68 million, this company’s outstanding shares have now reached $57.14 million.
Let’s look at the performance matrix of the company that is accounted for 26 employees.
AIM ImmunoTech Inc (AIM) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of AIM ImmunoTech Inc is 9.56%, while institutional ownership is 14.78%. The most recent insider transaction that took place on Sep 16 ’24, was worth 1,515. In this transaction CEO & President of this company bought 5,000 shares at a rate of $0.30, taking the stock ownership to the 1,493,042 shares. Before that another transaction happened on Sep 13 ’24, when Company’s CEO & President bought 20,000 for $0.31, making the entire transaction worth $6,160. This insider now owns 1,488,042 shares in total.
AIM ImmunoTech Inc (AIM) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 45.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.00% during the next five years compared to 42.86% growth over the previous five years of trading.
AIM ImmunoTech Inc (AMEX: AIM) Trading Performance Indicators
AIM ImmunoTech Inc (AIM) is currently performing well based on its current performance indicators. A quick ratio of 1.17 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 76.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.57, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.32 in one year’s time.
Technical Analysis of AIM ImmunoTech Inc (AIM)
AIM ImmunoTech Inc (AMEX: AIM) saw its 5-day average volume 0.61 million, a positive change from its year-to-date volume of 0.25 million. As of the previous 9 days, the stock’s Stochastic %D was 26.05%. Additionally, its Average True Range was 0.04.
During the past 100 days, AIM ImmunoTech Inc’s (AIM) raw stochastic average was set at 21.72%, which indicates a significant decrease from 38.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.26% in the past 14 days, which was lower than the 77.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3367, while its 200-day Moving Average is $0.4040. Nevertheless, the first resistance level for the watch stands at $0.3211 in the near term. At $0.3749, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4299. If the price goes on to break the first support level at $0.2123, it is likely to go to the next support level at $0.1573. The third support level lies at $0.1035 if the price breaches the second support level.
AIM ImmunoTech Inc (AMEX: AIM) Key Stats
Market capitalization of the company is 15.27 million based on 51,496K outstanding shares. Right now, sales total 200 K and income totals -28,960 K. The company made 50 K in profit during its latest quarter, and -1,840 K in sales during its previous quarter.
